STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #799 by analyst upside · 2026-06-27
CAMP
CAMP4 THERAPEUTICS CORPORATION
Healthcare · Market Cap $218M · P/E 0x
ANALYST PRICE TARGET
+104.4%
implied upside to consensus target
Current Price $4.2
Consensus Target $8.58
Bull Target $12.0
Bear Target $6.5
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
1
Sell
0
52-Week Low $1.32
52-Week High $7.75
YTD Return -30.0%
FUNDAMENTALS
Market Cap $218M
P/E Ratio (TTM) N/A
Forward P/E -5.4x
EPS (TTM) $-2.52
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.32
52-Week High $7.75
Current Price $4.2
Bear Target $6.5
Bull Target $12.0
● Now $4.2 ● Target $8.58
TRADING DATA
Avg Volume 99K
YTD Return -30.0%
Analyst Count 6
Consensus Buy
Upside to Target +104.4%
Last Updated 2026-06-27

ANALYST SUMMARY

CAMP4 THERAPEUTICS CORPORATION (CAMP) is currently trading at $4.2 with a Wall Street consensus price target of $8.58, implying potential upside of 104.4% over the next 12 months. 6 analysts currently cover CAMP, with a consensus rating of Buy - 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $6.5.

CAMP operates in the Healthcare sector with a market capitalisation of $218M. The stock is down 30.0% year-to-date and is currently trading near the lower end of its 52-week range of $1.32 – $7.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CAMP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan ↑ Upgrade
Neutral → Overweight 2026-06-16 43% win rate (7 calls)
Chardan Capital ● Initiated
Buy 2026-06-10 33% win rate (6 calls)
Rodman & Renshaw ● Initiated
Buy 2026-04-14 29% win rate (7 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2026-04-02 29% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2025-10-02 40% win rate (10 calls)
JP Morgan ↓ Downgrade
Overweight → Neutral 2025-09-16 43% win rate (7 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2025-09-15 14% win rate (7 calls)
Wedbush ● Initiated
Outperform 2025-05-27 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
15/30
Consensus clarity
4/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →